Two different families of TKi are currently approved: BTK inhibitors (BTKi) [80] (in first-line and relapsed/refractory CLL) and PI3K inhibitors (PI3Ki) (in relapsed/refractory CLL) [81]. This evidence concerns the gene PIK3CA and B-cell chronic lymphocytic leukemia.